Salazopyrin sulfasalazine 500mg tablet Australia - English - Department of Health (Therapeutic Goods Administration)

salazopyrin sulfasalazine 500mg tablet

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone; maize starch - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: salazopyrin en-tabs are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

PMS-SULFASALAZINE 500MG/TAB USP TABLET Canada - English - Health Canada

pms-sulfasalazine 500mg/tab usp tablet

pharmascience inc - sulfasalazine - tablet - 500mg - sulfasalazine 500mg - sulfonamides

PMS-SULFASALAZINE-E.C. TAB 500MG TABLET (ENTERIC-COATED) Canada - English - Health Canada

pms-sulfasalazine-e.c. tab 500mg tablet (enteric-coated)

pharmascience inc - sulfasalazine - tablet (enteric-coated) - 500mg - sulfasalazine 500mg - sulfonamides

AZULFIDINE EN-TABS- sulfasalazine tablet, delayed release United States - English - NLM (National Library of Medicine)

azulfidine en-tabs- sulfasalazine tablet, delayed release

pfizer laboratories div pfizer inc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - azulfidine en-tabs tablets are indicated: azulfidine en-tabs is particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. in patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. unlike anti-inflammatory drugs, azulfidine en-tabs does not produce an immediate response. concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of azulfidine en-tabs is apparent. azulfidine en-tabs tablets are contraindicated in: hypersensitivity to sulfasalazine, its metabolites, sulfonam

AZULFIDINE- sulfasalazine tablet United States - English - NLM (National Library of Medicine)

azulfidine- sulfasalazine tablet

pfizer laboratories div pfizer inc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - azulfidine tablets are indicated: azulfidine tablets are contraindicated in: none reported.

PYRALIN EN Sulfasalazine 500mg tablet Australia - English - Department of Health (Therapeutic Goods Administration)

pyralin en sulfasalazine 500mg tablet

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: white beeswax; propylene glycol; magnesium stearate; colloidal anhydrous silica; cellacefate; purified talc; macrogol 20000; povidone; carnauba wax; maize starch; glyceryl monostearate - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: pyralin en tablets are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).